IC
ASND icon

Ikarian Capital’s Ascendis Pharma A/S ASND Stock Holding History

Ikarian Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-70,000
Closed -$3.76M – 175
2020
Q1 		$3.76M Buy
+70,000
New +$9.1M 0.28% 74

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's ASND Position: Q3 2023 in Review

Ikarian Capital sold out of Ascendis Pharma A/S (ASND) in Q3 2023, closing a stake of 2,090 shares — an estimated $187K sold.

Ikarian Capital first reported a position in ASND in Q4 2020 and held it in 6 quarters. The position peaked at $14.5M in Q4 2020. 160 funds tracked by Wall St. Rank hold ASND as of Q3 2023.

  • Ikarian Capital reported no remaining Ascendis Pharma A/S position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 2,090 Ascendis Pharma A/S shares in Q3 2023, an estimated $187K.
  • Ikarian Capital first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 6 quarters.
  • Ikarian Capital's Ascendis Pharma A/S position peaked at $14.5M in Q4 2020.
  • 160 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.